title: Awakening of "Schlafen11" to Tackle Chemotherapy Resistance in SCLC.
abstract: Chemotherapy resistance arises invariably in small cell lung cancer (SCLC). In this issue of Cancer Cell, Gardner et al. find that in some SCLC, EZH2 mediates resistance via downregulation of Schlafen11 (SLFN11). Combining EZH2 inhibition with chemotherapy effectively overcomes drug resistance of xenografted SCLC, holding promise for new treatment paradigms.
authors.affiliation: The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: k.berns@nki.nl.
authors.forename: Katrien
authors.initials: K
authors.lastname: Berns
authors.affiliation: The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: a.berns@nki.nl.
authors.forename: Anton
authors.initials: A
authors.lastname: Berns
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D015536:Down-Regulation; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy*